ALLEGRO-DVT/V-NOVA
Allegro DVT, the leading provider of video codec compliance test suites and semiconductor video IPs, and V-Nova, a leading provider of video compression solutions today announce a partnership to accelerate the availability of LCEVC enabled solutions for Video SOCs and ASIC vendors looking at faster time-to-market in the deployment of LCEVC.
The two companies will collaborate to address the growing demand for LCEVC with a target to make available both compliance test streams and proven video IPs. This new product roadmap will enable video SOC and video ASIC vendors in a multitude of different markets to integrate and verify the compliance of their LCVEC implementation with the standard, allowing for a safer tape-out and faster time-to-market.
Nouar Hamze, CEO, Allegro DVT said, “We were impressed with the performance of LCEVC both in terms of video quality and compression ratio. We also see it as an opportunity to tackle the increasing complexity of video codecs while delivering best-in-class power consumption. Allegro DVT is committed to supporting the LCEVC ecosystem and welcome the collaboration with V-Nova. Over the next months, we will be announcing a full range of new products to accelerate the design and testing of video SoCs targeting the LCEVC market.”
“We are excited to be collaborating with Allegro DVT to support the roll out of LCEVC in the market,” said Guido Meardi, CEO and co-founder at V-Nova. “They are the market leaders in the provision of compliance test streams to SOC vendors. These, together with proven silicon IP, will speed up the availability of LCEVC-enabled silicon in the market. We look forward to the partnership and further support Allegro’s LCEVC roadmap.”
LCEVC – the new video standard from MPEG – is at the vanguard of improving image quality, reducing latency, and boosting bandwidth. LCEVC is the first enhancement standard from MPEG, delivering better quality at up to 40% lower bandwidth, faster transcoding times, reduced costs for storage and content delivery. MPEG-5 LCEVC is an innovative standard that enhances any ‘base’ codec, including AVC/H.264, HEVC/H.265, VVC/H.266 and AV1 with no requirement to replace them.
About Allegro DVT
Allegro DVT, headquartered in Grenoble/France, is a world leading provider of digital video technology solutions including compliance streams and video codec semiconductor IPs focused on the H.264/AVC, H.265/HEVC, AVS2, AVS3, VP9, AV1 and VVC standards.
About V-Nova
V-Nova is committed to unlocking higher picture quality at scale. Its technologies, based on the innovative use of AI and parallel processing improve data, video, imaging, point-cloud compression and have been granted international standard status by MPEG, ISO and SMPTE. Our relentless investment in R&D has built a portfolio of over 600 international patents which we monetize through software licensing, IP royalties and product sales. For more about V-Nova, please visit: www.v-nova.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005048/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 14:05:00 CEST | Press release
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model3.7.2025 12:02:00 CEST | Press release
The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702168211/en/ In 10-20% of tinnitus cases, the noise in the ear is so severe that it significantly impairs the quality of life of those affected. (Source: AI-generated) In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, th
H2SITE Secures EIC Accelerator Funding to Deploy a Flagship 1 TPD Ammonia Cracker Using Membrane Reactor Technology at a Port in North-West Europe3.7.2025 08:40:00 CEST | Press release
H2SITE has been awarded the EIC (European Innovation Council) Accelerator program for a project aimed at deploying a first-of-its-kind ammonia cracking unit capable of producing 1 ton of high-purity hydrogen per day. The system is based on H2SITE’s proprietary palladium-based membrane reactor technology, which enables the simultaneous catalytic decomposition of ammonia and selective hydrogen separation within a single unit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702142283/en/ Ammonia Cracker using Membrane Reactor Technology This breakthrough technology offers several compelling advantages over conventional ammonia cracking processes: Lowest Levelized Cost of Hydrogen (LCOH) from ammonia due to high efficiency and integrated operation Reduced energy consumption, operating at significantly lower temperatures (400–450 °C) than traditional cracking methods (typically 600–800 °C) High-purity hydrogen output, compliant
Curve Pay and Thales Join Forces to Securely Transform Digital Wallets on iPhone3.7.2025 08:00:00 CEST | Press release
This collaboration between Curve and Thales provides iOS users with greater control, flexibility, autonomy and digital-security for in-store contactless payments and digital wallets Curve, the ultimate digital wallet, today announced deepening its collaboration with Thales, the global leader in advanced technologies, delivering secure modern payment solutions for financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702696837/en/ Thales D1 Platform to power CURVE PAY (Photo: Thales) This partnership comes on the back of Curve launching Curve Pay on iOS, marking a watershed moment in mobile payments. This partnership is a significant step to reshaping everyday spending, allowing Curve customers to benefit from NFC payment directly in the Curve App for contactless payments in store for all end-users on iOS and Android. Curve Pay is underpinned by Thales’ D1 platform on iOS and Android in Europe which allows
Medimaps Group Launches In Europe TBS Osteo Next-Generation Software For Advanced Bone Microarchitecture Assessment3.7.2025 08:00:00 CEST | Press release
New TBS Osteo Advanced next-generation software enhances fracture risk detection beyond standard of care in osteoporosis, a silent disease affecting over 32 million Europeans1 TBS Osteo Advanced next-generation software to be rolled-out across Europe Broad clinical adoption reinforces TBS Osteo leadership in bone microarchitecture evaluation for fracture risk assessment Subscription-based model offers ongoing services and access to future clinical innovations Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, announces the European launch of its MDR-cleared next-generation TBS Osteo Advanced software. Following the product launch in the United States last month, this next milestone reflects the company's commitment to advancing osteoporosis detection and bone health management worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702082335/en/ Medimaps' TBS Osteo next-generatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom